BioCryst Pharmaceutical Inc. (BCRX)

HEALTH CARE: PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

4505 EMPEROR BOULEVARD DURHAM, NC 27703

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.

Data as of 2021-08-02 07:48:47 -0400
Market Cap2.864 Billion Shares Outstanding177.696 Million Avg 30-day Volume2.363 Million
P/E Ratio-13.67294 Dividend Yield EPS-1.21
Price/Sales89.38 Debt to Equity-3.79 EBITDA-184.448 Million
Price to Book Value-38.2 Forward PE-0.09 Enterprise Value2.908 Billion
Total Cash240.356 Million Current Debt101.201 Million Gross Profit24.575 Million
BETA1.62959 52-week High/Low17.74 / 3.3 Next Earnings Date2021-08-05 Price to Cash FLow (P/CF) -43.662
Data provided by IEX Cloud
View SEC Filings from BCRX instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 3 3 0.0% 3 (0.18%) 3 (0.17%) 0.0%
Funds Holding: 185 174 6.32% 53 (3.11%) 55 (3.19%) -3.64%
13F shares: 104.245 Million 120.441 Million -13.45% 48.329 Million 62.66 Million -22.87%
% Ownership 58.7222 68.2129 -13.91% 27.2244 35.4883 -23.29%
New Positions: 44 38 15.79% 14 14 0.0%
Increased Positions 55 57 -3.51% 14 16 -12.5%
Closed Positions 32 15 113.33% 16 6 166.67%
Reduced Positions 69 56 23.21% 23 20 15.0%
Total Calls 3.727 Million 1.561 Million 138.78% 803.8 Thousand 172 Thousand 367.33%
Total Puts 2.307 Million 1.483 Million 55.58% 718 Thousand 409.2 Thousand 75.46%
PUT/CALL Ratio 0.62 0.95 -34.74% 0.89 2.38 -62.61%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding BCRX (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding BCRX BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

28.3 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

28.3 Thousand total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MILANO VINCENT

  • Director
10,000 2021-07-26 2

ABERCROMBIE GEORGE B

  • Director
8,000 2021-07-15 4

HUTSON NANCY J

  • Director
65,073 2021-06-10 6

INGRAM ROBERT ALEXANDER

  • Director
76,201 2021-05-28 5

HEGGIE THERESA

  • Director
14,166 2021-05-28 5

ASELAGE STEVE

  • Director
32,130 2021-05-28 5

SHERIDAN WILLIAM P CHIEF MEDICAL OFFICER

  • Officer
120,764 2021-05-27 4

LEE KENNETH B JR

  • Director
40,000 2021-05-25 1

LEVIN ALAN G

  • Director
40,000 2021-05-25 1

BARNES ALANE P CHIEF LEGAL OFFICER

  • Officer
292,254 2021-05-11 5

THACKRAY HELEN M. CHIEF R&D OFFICER

  • Officer
  • Director
500,000 2021-03-31 1

JONES MICHAEL L EXEC. DIRECTOR, FINANCE - PAO

  • Officer
5,348 2021-03-18 3

BABU YARLAGADDA S SENIOR VP - DRUG DISCOVERY

  • Officer
183,156 2021-02-19 3

STONEHOUSE JON P PRESIDENT & CEO

  • Officer
  • Director
784,086 2020-12-15 2

SNIECINSKI MEGAN CHIEF BUSINESS OFFICER

  • Officer
0 2020-12-15 1

GAYER CHARLES K VICE PRESIDENT AND CCO

  • Officer
0 2020-12-15 1

DOYLE ANTHONY CHIEF FINANCIAL OFFICER

  • Officer
0 2020-12-15 2

STAAB THOMAS R II SENIOR VICE PRESIDENT AND CFO

  • Officer
0 2020-02-21 0

POWELL LYNNE SENIOR VP - CCO

  • Officer
0 2019-01-25 0

ERCK STANLEY C

  • Director
48,333 2018-11-28 0

COHEN FRED E

  • Director
0 2018-06-20 0

PATEL SANJ K

  • Director
0 2017-05-24 0

BAKER BROS. ADVISORS LP

BAKER BROS. ADVISORS (GP) LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
11,016,695 2016-08-12 0

SANDERS CHARLES A

  • Director
12,971 2016-02-29 0

JENSEN PEDER

  • Director
0 2014-05-02 0

BAKER FELIX

BAKER BROS. INVESTMENTS II, L.P.

BAKER/TISCH INVESTMENTS, LP

667, L.P.

BAKER BROTHERS LIFE SCIENCES LP

14159, L.P.

BAKER BROS. ADVISORS LP

BAKER JULIAN

BAKER BROS. ADVISORS (GP) LLC

BAKER BROS. INVESTMENTS, L.P.

  • 10% Owner
6,699,979 2013-08-01 0

BAKER BROS. ADVISORS (GP) LLC

  • 10% Owner
0 2013-07-01 0

HOROVITZ ZOLA P

  • Director
0 2012-05-23 0

HIGGINS JOHN L

  • Director
0 2012-05-23 0

BAKER BROS ADVISORS LLC

  • 10% Owner
0 2012-04-12 0

MCCULLOUGH DAVID VP

  • Officer
24,124 2012-03-15 0

LOWREY ROBERT S CONTROLLER, PAO

  • Officer
9,766 2012-03-15 0

BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
3,841,124 2011-06-30 0

BAKER BROS. CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
62,407 2011-06-30 0

BIGGAR STEPHEN R

  • Director
0 2011-05-12 0

GRANT STUART SR VP & CFO

  • Officer
57,102 2011-03-16 0

SEIDENBERG BETH C

  • Director
0 2010-05-13 0

FEATHERINGILL WILLIAM W

  • Director
  • 10% Owner
0 2010-05-13 0

MILLS MIKE PRINCIPAL ACCOUNTING OFFICER

  • Officer
0 2010-03-12 0

BAKER / TISCH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
17,241 2009-05-28 0

14159 CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
120,828 2009-05-28 0

BAKER BIOTECH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
1,522,015 2009-05-28 0

DARWIN MICHAEL A PRINCIPAL ACCOUNTING OFFICER

  • Officer
3,048 2008-07-31 0

STEER RANDOLPH C

  • Director
0 2008-05-21 0

BENNETT J CLAUDE CHIEF OPERATING OFFICER

  • Officer
  • Director
0 2008-03-14 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

MILANO VINCENT - Director

2021-07-28 18:31:26 -0400 2021-07-26 A 66,667 a 66,667 direct

ABERCROMBIE GEORGE B - Director

2021-07-19 16:39:54 -0400 2021-07-15 M 5,000 $2.63 a 8,000 direct 1.7857 3.4483 6.2808 4 0.0 1

ABERCROMBIE GEORGE B - Director

2021-07-19 16:39:54 -0400 2021-07-15 M 5,000 d 5,000 direct

ABERCROMBIE GEORGE B - Director

2021-07-19 16:39:54 -0400 2021-07-15 S 5,000 $15.69 d 3,000 direct 1.7857 3.4483 6.2808 4 0.0 1

HUTSON NANCY J - Director

2021-06-14 16:29:33 -0400 2021-06-10 M 8,333 $2.85 a 73,406 direct 3.0109 6.6624 7.7514 10.5701 28 -1.3453 24

HUTSON NANCY J - Director

2021-06-14 16:29:33 -0400 2021-06-10 S 23,333 $16.86 d 65,073 direct 3.0109 6.6624 7.7514 10.5701 28 -1.3453 24

HUTSON NANCY J - Director

2021-06-14 16:29:33 -0400 2021-06-10 M 15,000 d 0 direct

HUTSON NANCY J - Director

2021-06-14 16:29:33 -0400 2021-06-10 M 15,000 $3.32 a 88,406 direct 3.0109 6.6624 7.7514 10.5701 28 -1.3453 24

HUTSON NANCY J - Director

2021-06-14 16:29:33 -0400 2021-06-10 M 8,333 d 0 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 22:15:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 21:45:04 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 21:15:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 20:45:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 20:15:04 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 19:45:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 19:15:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 18:45:04 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 18:15:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 17:45:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 17:15:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 16:45:04 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 16:15:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 15:45:02 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 15:15:04 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 14:45:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 14:15:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 13:45:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 13:15:03 UTC -0.1709 0.2509 2400000
BIOCRYST PHARMACEUTICALS INC BCRX 2021-08-04 12:45:03 UTC -0.1709 0.2509 2400000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund BCRX -10381.0 shares, $-105574.77 2021-03-31 N-PORT
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund BCRX -61211.0 shares, $-712189.99 2021-04-30 N-PORT

Elevate your investments